The role of interleukin 10 in the pathogenesis and potential treatment of skin diseases

Journal of the American Academy of Dermatology

Volumn 50, Issue 5, 2004, Pages 657-675

  Weiss, Elliot ^a   Mamelak, Adam Joseph ^a   La Morgia, Stephania ^b   Wang, Binghe ^a   Feliciani, Claudio ^c   Tulli, Antonio ^b   Sauder, Daniel Nathan ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF CHIETI   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 10;

ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL DIFFERENTIATION; CELL GROWTH; EFFECTOR CELL; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; MAST CELL; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SKIN DISEASE; SKIN INFECTION; SKIN TUMOR; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL;

EID: 2342451964     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2003.11.075     Document Type: Review

References (193)

1. Baraniuk JN, Kowalski ML, Kaliner MA. Neuropeptides in the skin. In: Bos JD, editor. Skin immune system (SIS). London: CRC Press; 1990. p. 307-26.
2. Grone A. Keratinocytes and cytokines. Vet Immunol Immunopathol 2002;88:1-12.
3. Balkwill FR, Burke F. The cytokine network. Immunol Today 1989;10:299-304.
4. Luger TA, Schwarz T, Krutmann J, Kock A, Urbanski A, Kirnbauer R. Cytokines and the skin. Curr Probl Dermatol 1990;19:35-49.
5. McKenzie RC, Sauder DN. The role of keratinocyte cytokines in inflammation and immunity. J Invest Dermatol 1990; 95(Suppl):105S-7S.
6. Sauder DN. The role of epidermal cytokines in inflammatory skin diseases. J Invest Dermatol 1990;95(Suppl):275-8S.
7. Weckmann AL, Alcocer-Varela J. Cytokine inhibitors in autoimmune disease. Semin Arthritis Rheum 1996;26:539-57.
8. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989;170:2081-95.
9. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991;146: 3444-51.
10. Asadullah K, Sterry W, Trefzer U. Cytokine therapy in dermatology. Exp Dermatol 2002;11:97-106.
11. Borish LC, Steinke JW. Cytokines and chemokines. J Allergy Clin Immunol 2003;111 (Suppl):S460-75.
12. Asadullah K, Sabat R, Wiese A, Docke WD, Volk HD, Sterry W. Interleukin-10 in cutaneous disorders: implications for its pathophysiological importance and therapeutic use. Arch Dermatol Res 1999;291:628-36.
13. Luger TA, Schwarz T. Therapeutic use of cytokines in dermatology. J Am Acad Dermatol 1991;24:915-26.
14. Fickenscher H, Hor S, Kupers H, Knappe A, Wittmann S, Sticht H, The interleukin-10 family of cytokines. Trends Immunol 2002; 23:89-96.
15. Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy - review of a new approach. Pharmacol Rev 2003;55:241-69.
16. Dumoutier L, Louahed J, Renauld JC. Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. J Immunol 2000;164:1814-9.
17. Knappe A, Hor S, Wittmann S, Fickenscher H. Induction of a novel cellular homolog of interleukin-10, AK155, by transformation of T lymphocytes with herpesvirus saimiri. J Virol 2000; 74:3881-7.
18. Liao YC, Liang WG, Chen FW, Hsu JH, Yang JJ, Chang MS. IL-19 induces production of IL-6 and TNF-alpha and results in cell apoptosis through TNF-alpha. J Immunol 2002;169:4288-97.
19. Blumberg H, Conklin D, Xu WF, Grossmann A, Brender T, Carollo S, et al. Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell 2001;104:9-19.
20. Huang EY, Madireddi MT, Gopalkrishnan RV, Leszczyniecka M, Su Z, Lebedeva IV, et al. Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties. Oncogene 2001;20:7051-63.
21. Platzer C, Meisel C, Vogt K, Platzer M, Volk HD. U p-regulation of monocytic IL-10 by tumor necrosis factor-alpha and cAMP elevating drugs. Int Immunol 1995;7:517-23.
22. Lauw FN, Pajkrt D, Hack CE, Kurimoto M, van Deventer SJ, van der Poll T. Proinflammatory effects of IL-10 during human endotoxemia. J Immunol 2000;165:2783-9.
23. Meisel C, Vogt K, Platzer C, Randow F, Liebenthal C, Volk HD. Differential regulation of monocytic tumor necrosis factor-alpha and interleukin-10 expression. Eur J Immunol 1996;26:1580-6.
24. Woiciechowsky C, Asadullah K, Nestler D, Eberhardt B, Platzer C, Schoning B, et al. Sympathetic activation triggers systemic interleukin-10 release in immunodepression induced by brain injury. Nat Med 1998;4:808-13.
25. Riese U, Brenner S, Docke WD, Prosch S, Reinke P, Oppert M, et al. Catecholamines induce IL-10 release in patients suffering from acute myocardial infarction by transactivating its promoter in monocytic but not in T-cells. Mol Cell Biochem 2000; 212:45-50.
26. Moore KW, O'Garra A, de Waal MR, Vieira P, Mosmann TR. Interleukin-10. Annu Rev Immunol 1993;11:165-90.
27. Michel G, Gailis A, Jarzebska-Deussen B, Muschen A, Mirmohammadsadegh A, Ruzicka T. 1,25-(OH)2-vitamin D3 and calcipotriol induce IL-10 receptor gene expression in human epidermal cells. Inflamm Res 1997;46:32-4.
28. Joss A, Akdis M, Faith A, Blaser K, Akdis CA. IL-10 directly acts on T cells by specifically altering the CD28 co-stimulation pathway. Eur J Immunol 2000;30:1683-90.
29. Seifert M, Gruenberg BH, Sabat R, Donner P, Gruetz G, Volk HD, et al. Keratinocyte unresponsiveness towards interleukin-10: lack of specific binding due to deficient IL-10 receptor 1 expression. Exp Dermatol 2003;12:137-44.
30. Seifert M, Sterry W, Effenberger E, Rexin A, Friedrich M, Haeussler-Quade A, et al. The antipsoriatic activity of IL-10 is rather caused by effects on peripheral blood cells than by a direct effect on human keratinocytes. Arch Dermatol Res 2000;292: 164-72.
31. Michel G, Mirmohammadsadegh A, Olasz E, Jarzebska-Deussen B, Muschen A, Kemeny L, et al. Demonstration and functional analysis of IL-10 receptors in human epidermal cells: decreased expression in psoriatic skin, down-modulation by IL-8, and up-regulation by an antipsoriatic glucocorticosteroid in normal cultured keratinocytes. J Immunol 1997;159:6291-7.
32. Becherel PA, Le Goff L, Ktorza S, Ouaaz F, Mencia-Huerta JM, Dugas B, et al. Interleukin-10 inhibits IgE-mediated nitric oxide synthase induction and cytokine synthesis in normal human keratinocytes. Eur J Immunol 1995;25:2992-5.
33. Giustizieri ML, Scarponi C, Albanesi C, Girolomoni G. Human keratinocytes express functional IL-10 receptor after prolonged treatment with IFN-gamma [abstract]. J Invest Dermatol 2003;121:abstract 0935.
34. Finbloom DS, Winestock KD. IL-10 induces the tyrosine phosphorylation of tyk2 and Jak1 and the differential assembly of STAT1 alpha and STAT3 complexes in human T cells and monocytes. J Immunol 1995;155:1079-90.
35. Shen X, Hong F, Nguyen VA, Gao B. IL-10 attenuates IFN-alpha-activated STAT1 in the liver: involvement of SOCS2 and SOCS3. FEBS Lett 2000;480:132-6.
36. Ding Y, Chen D, Tarcsafalvi A, Su R, Qin L, Bromberg JS. Suppressor of cytokine signaling 1 inhibits IL-10-mediated immune responses. J Immunol 2003;170:1383-91.
37. Wang P, Wu P, Siegel MI, Egan RW, Billah MM. Interleukin (IL)-10 inhibits nuclear factor kappa B (NF kappa B) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem 1995;270:9558-63.
38. Schottelius AJ, Mayo MW, Sartor RB, Baldwin AS, Jr. Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J Biol Chem 1999;274: 31868-74.
39. Romagnani S. Biology of human TH1 and TH2 cells. J Clin Immunol 1995;15:121-9.
40. MacNeil IA, Suda T, Moore KW, Mosmann TR, Zlotnik A. IL-10, a novel growth cofactor for mature and immature T cells. J Immunol 1990;145:4167-73.
41. D'Andrea A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M, Trinchieri G. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 1993;178:1041-8.
42. Ralph P, Nakoinz I, Sampson-Johannes A, Fong S, Lowe D, Min HY, et al. IL-10, T lymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor. J Immunol 1992; 148:808-14.
43. de Waal MR, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991;174:1209-20.
44. Redpath S, Ghazal P, Gascoigne NR. Hijacking and exploitation of IL-10 by intracellular pathogens. Trends Microbiol 2001;9: 86-92.
45. Beissert S, Hosoi J, Kuhn R, Rajewsky K, Muller W, Granstein RD. Impaired immunosuppressive response to ultraviolet radiation in interleukin-10-deficient mice. J Invest Dermatol 1996; 107:553-7.
46. Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest 2000; 117:1162-72.
47. Akdis CA, Blaser K. Mechanisms of interleukin-10-mediated immune suppression. Immunology 2001;103:131-6.
48. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991;147:3815-22.
49. Buelens C, Verhasselt V, De Groote D, Thielemans K, Goldman M, Willems F. Interleukin-10 prevents the generation of dendritic cells from human peripheral blood mononuclear cells cultured with interleukin-4 and granulocyte/macrophage-colony-stimulating factor. Eur J Immunol 1997;27:756-62.
50. Allavena P, Piemonti L, Longoni D, Bernasconi S, Stoppacciaro A, Ruco L, et al. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol 1998;28:359-69.
51. Macatonia SE, Doherty TM, Knight SC, O'Garra A. Differential effect of IL-10 on dendritic cell-induced T cell proliferation and IFN-gamma production. J Immunol 1993;150:3755-65.
52. Go NF, Castle BE, Barrett R, Kastelein R, Dang W, Mosmann TR, et al. Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X chromosome-linked immunodeficiency B cells. J Exp Med 1990;172:1625-31.
53. Thompson-Snipes L, Dhar V, Bond MW, Mosmann TR, Moore KW, Rennick DM. Interleukin 10: a novel stimulatory factor for mast cells and their progenitors. J Exp Med 1991;173:507-10.
54. Carson WE, Lindemann MJ, Baiocchi R, Linett M, Tan JC, Chou CC, et al. The functional characterization of interleukin-10 receptor expression on human natural killer cells. Blood 1995;85: 3577-85.
55. Spits H, de Waal MR. Functional characterization of human IL-10. Int Arch Allergy Immunol 1992;99:8-15.
56. Tojo N, Yoshimura N, Yoshizawa M, Ichioka M, Chida M, Miyazato I, et al. Vitiligo and chronic photosensitivity in human immunodeficiency virus infection. Jpn J Med 1991;30:255-9.
57. Kreuter A, Schugt I, Hartmann M, Rasokat H, Altmeyer P, Brockmeyer NH. Dermatological diseases and signs of HIV infection. Eur J Med Res 2002;7:57-62.
58. Vafai A, Berger M. Zoster in patients infected with HIV: a review. Am J Med Sci 2001;321:372-80.
59. Fidel PL Jr. Immunity to Candida. Oral Dis 2002;8(Suppl 2):69-75.
60. Mallon E, Bunker CB. HIV-associated psoriasis. AIDS Patient Care STDS 2000;14:239-46.
61. Nguyen P, Vin-Christian K, Ming ME, Berger T. Aggressive squamous cell carcinomas in persons infected with the human immunodeficiency virus. Arch Dermatol 2002;138:758-63.
62. Bennasser Y, Bahraoui E. HIV-1 Tat protein induces interleukin-10 in human peripheral blood monocytes: involvement of protein kinase C-betaII and -delta. FASEB J 2002;16:546-54.
63. Tangsinmankong N, Day NK, Good RA, Haraguchi S. Different mechanisms are utilized by HIV-1 Nef and staphylococcal enterotoxin A to control and regulate interleukin-10 production. Immunol Lett 2002;84:97-101.
64. Sozzani S, Ghezzi S, Iannolo G, Luini W, Borsatti A, Polentarutti N, et al. Interleukin 10 increases CCR5 expression and HIV infection in human monocytes. J Exp Med 1998;187:439-44.
65. Ostrowski MA, Gu JX, Kovacs C, Freedman J, Luscher MA, MacDonald KS. Quantitative and qualitative assessment of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ Tcell immunity to gag in HIV-1-infected individuals with differential disease progression: reciprocal interferon-gamma and interleukin-10 responses. J Infect Dis 2001;184:1268-78.
66. Smolnikova MV, Konenkov VI. Association of IL2, TNFA, IL4 and IL10 promoter gene polymorphisms with the rate of progression of the HIV Infection. Russ J Immunol 2002;7:349-56.
67. Rodrigues DS, Brunialti MK, Medeiros EA, Diaz RS, Turcato G, Salomao R. Induction of interleukin-10 by HIV antigens in peripheral mononuclear cells of health care workers after occupational exposure to HIV-1-positive blood. Braz J Med Biol Res 2002;35:697-701.
68. Parato KG, Kumar A, Badley AD, Sanchez-Dardon JL, Chambers KA, Young CD, et al. Normalization of natural killer cell function and phenotype with effective anti-HIV therapy and the role of IL-10. AIDS 2002;16:1251-6.
69. Trabattoni D, Lo CS, Biasin M, Seminari E, Di Pietro M, Ravasi G, et al. Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients. Clin Diagn Lab Immunol 2002;9:1114-8.
70. Stylianou E, Aukrust P, Nordoy I, Muller F, Froland SS. Enhancement of lymphocyte proliferation induced by interleukin-12 and anti-interleukin-10 in HIV-infected patients during highly active antiretroviral therapy. APMIS 2000;108:601-7.
71. Reuben JM, Lee BN, Paul M, Kline MW, Cron SG, Abramson S, et al. Magnitude of IFN-gamma production in HIV-1-infected children is associated with virus suppression. J Allergy Clin Immunol 2002;110:255-61.
72. Tchou I, Misery L, Sabido O, Dezutter-Dambuyant C, Bourlet T, Moja P, et al. Functional HIV CXCR4 coreceptor on human epithelial Langerhans cells and infection by HIV strain X4. J Leukoc Biol 2001;70:313-21.
73. Ancuta P, Bakri Y, Chomont N, Hocini H, Gabuzda D, Haeffner-Cavaillon N. Opposite effects of IL-10 on the ability of dendritic cells and macrophages to replicate primary CXCR4-dependent HIV-1 strains. J Immunol 2001;166:4244-53.
74. Smith KJ, Skelton HG, Nelson A, Wagner KF, Hackley BE Jr. Preservation of allergic contact dermatitis to poison ivy (urushiol) in late HIV disease. The implications and relevance to immunotherapy with contact allergens. Dermatology 1997;195:145-9.
75. Creery D, Angel JB, Aucoin S, Weiss W, Cameron WD, Diaz-Mitoma F, et al. Nef protein of human immunodeficiency virus and lipopolysaccharide induce expression of CD14 on human monocytes through differential utilization of interleukin-10. Clin Diagn Lab Immunol 2002;9:1212-21.
76. Arany I, Grattendick KG, Tyring SK. Interleukin-10 induces transcription of the early promoter of human papillomavirus type 16 (HPV16) through the 5′-segment of the upstream regulatory region (URR). Antiviral Res 2002;55:331-9.
77. Haig DM, Thomson J, McInnes CJ, Deane DL, Anderson IE, McCaughan CA, et al. A comparison of the anti-inflammatory and immuno-stimulatory activities of orf virus and ovine interleukin-10. Virus Res 2002;90:303-16.
78. Moore KW, Vieira P, Fiorentino DF, Trounstine ML, Khan TA, Mosmann TR. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science 1990;248: 1230-4.
79. Fleming SB, McCaughan CA, Andrews AE, Nash AD, Mercer AA. A homolog of interleukin-10 is encoded by the poxvirus orf virus. J Virol 1997;71:4857-61.
80. Lateef Z, Fleming S, Halliday G, Faulkner L, Mercer A, Baird M. Orf virus-encoded interleukin-10 inhibits maturation, antigen presentation and migration of murine dendritic cells. J Gen Virol 2003;84:1101-9.
81. Lehmann J, Enssle KH, Lehmann I, Emmendorfer A, Lohmann-Matthes ML. The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice. J Interferon Cytokine Res 2000;20:63-77.
82. Kemp K, Theander TG, Hvlid L, Garfar A, Kharazmi A, Kemp M. Interferon-gamma- and tumour necrosis factor-alpha-producing cells in humans who are immune to cutaneous leishmaniasis. Scand J Immunol 1999;49:655-9.
83. Kemp K, Kemp M, Kharazmi A, Ismail A, Kurtzhals JA, Hviid L, et al. Leishmania-specific T cells expressing interferon-gamma (IFN-gamma) and IL-10 upon activation are expanded in individuals cured of visceral leishmaniasis. Clin Exp Immunol 1999; 116:500-4.
84. Santos-Gomes GM, Rosa R, Leandro C, Cortes S, Romao P, Silveira H. Cytokine expression during the outcome of canine experimental infection by Leishmania infantum. Vet Immunol Immunopathol 2002;88:21-30.
85. Bacellar O, D'oliveira A Jr, Jeronimo S, Carvalho EM. IL-10 and IL-12 are the main regulatory cytokines in visceral leishmaniasis. Cytokine 2000;12:1228-31.
86. Gaafar A, Veress B, Permin H, Kharazmi A, Theander TG, El Hassan AM. Characterization of the local and systemic immune responses in patients with cutaneous leishmaniasis due to Leishmania major. Clin Immunol 1999;91:314-20.
87. Gomes NA, Barreto-de-Souza V, DosReis GA. Early in vitro priming of distinct T(h) cell subsets determines polarized growth of visceralizing Leishmania in macrophages. Int Immunol 2000; 12:1227-33.
88. Kane MM, Mosser DM. The role of IL-10 in promoting disease progression in leishmaniasis. J Immunol 2001;166:1141-7.
89. Kima PE, Constant SL, Hannum L, Colmenares M, Lee KS, Haberman AM, et al. Internalization of Leishmania mexicana complex amastigotes via the Fc receptor is required to sustain infection in murine cutaneous leishmaniasis. J Exp Med 2000;191: 1063-8.
90. Araujo Z, Heremans H, Stordeur P, Wissing M, Goldman M, Castes M, et al. IFN-gamma, IL-4, IL-10 and IL-12 gene expression in BCG-Leishmania vaccination of Trypanosoma cruzi-infected mice. Vaccine 2000;18:1822-9.
91. Murray HW, Lu CM, Mauze S, Freeman S, Moreira AL, Kaplan G, et al. Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect Immun 2002;70:6284-93.
92. Awasthi A, Mathur R, Khan A, Joshi BN, Jain N, Sawant S, et al. CD40 signaling is impaired in L. major-infected macrophages and is rescued by a p38MAPK activator establishing a host-protective memory T cell response. J Exp Med 2003;197:1037-43.
93. De Almeida MC, Cardoso SA, Barral-Netto M. Leishmania (Leishmania) chagasi infection alters the expression of cell adhesion and costimulatory molecules on human monocyte and macrophage. Int J Parasitol 2003;33:153-62.
94. Yue FY, Dummer R, Geertsen R, Hofbauer G, Laine E, Manolio S, et al. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer 1997;71:630-7.
95. Matsuda M, Salazar F, Petersson M, Masucci G, Hansson J, Pisa P, et al. Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J Exp Med 1994;180:2371-6.
96. Nadler R, Luo Y, Zhao W, Ritchey JK, Austin JC, Cohen MB, et al. Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guerin (BCG) mediated antitumour activity. Clin Exp Immunol 2003;131:206-16.
97. Sieling PA, Wang XH, Gately MK, Oliveros JL, McHugh T, Barnes PF, et al. IL-12 regulates T helper type 1 cytokine responses in human infectious disease. J Immunol 1994;153:3639-47.
98. Lima MC, Pereira GM, Rumjanek FD, Gomes HM, Duppre N, Sampaio EP, et al. Immunological cytokine correlates of protective immunity and pathogenesis in leprosy. Scand J Immunol 2000;51:419-28.
99. Hussain R, Kifayet A, Dojki M, Dockrell HM. Selective correlation of interferon-gamma, tumour necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor with immunoglobulin G1 and immunoglobulin G3 subclass antibody in leprosy. Immunology 1999;98:238-43.
100. Yamauchi PS, Bleharski JR, Uyemura K, Kim J, Sieling PA, Miller A, et al. A role for CD40-CD40 ligand interactions in the generation of type 1 cytokine responses in human leprosy. J Immunol 2000;165:1506-12.
101. Misra N, Selvakumar M, Singh S, Bharadwaj M, Ramesh V, Misra RS, et al. Monocyte derived IL 10 and PGE2 are associated with the absence of Th1 cells and in vitro T cell suppression in lepromatous leprosy. Immunol Lett 1995;48:123-8.
102. Libraty DH, Airan LE, Uyemura K, Jullien D, Spellberg B, Rea TH, et al. Interferon-gamma differentially regulates interleukin-12 and interleukin-10 production in leprosy. J Clin Invest 1997;99: 336-41.
103. Amel Kashipaz MR, Huggins ML, Lanyon P, Robins A, Powell RJ, Todd I. Assessment of Be1 and Be2 cells in systemic lupus erythematosus indicates elevated interleukin-10 producing CD5+ B cells. Lupus 2003;12:356-63.
104. Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, Howard M. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 1994;179:305-10.
105. Park YB, Lee SK, Kim DS, Lee J, Lee CH, Song CH. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 1998;16:283-8.
106. Llorente L, Zou W, Levy Y, Richaud-Patin Y, Wijdenes J, Alcocer-Varela J, et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995;181:839-44.
107. Cairns AP, Crockard AD, Bell AL. Interleukin-10 receptor expression in systemic lupus erythematosus and rheumatoid arthritis. Clin Exp Rheumatol 2003;21:83-6.
108. Westendorp RG, Langermans JA, Huizinga TW, Verweij CL, Sturk A. Genetic influence on cytokine production in meningococcal disease. Lancet 1997;349:1912-3.
109. Eskdale J, Wordsworth P, Bowman S, Field M, Gallagher G. Association between polymorphisms at the human IL-10 locus and systemic lupus erythematosus. Tissue Antigens 1997;49: 635-9. Erratum in Tissue Antigens 1997;50:699.
110. Eskdale J, Wordsworth P, Bowman S, Field M, Gallagher G. Association between polymorphisms at the human IL-10 locus and systemic lupus erythematosus. Tissue Antigens 1997;49: 635-9. Erratum in Tissue Antigens 1997;50:699.
111. Mehrian R, Quismorio FP Jr, Strassmann G, Stimmler MM, Horwitz DA, Kitridou RC, et al. Synergistic effect between IL-10 and bcl-2 genotypes in determining susceptibility to systemic lupus erythematosus. Arthritis Rheum 1998;41:596-602.
112. D'Alfonso S, Rampi M, Bocchio D, Colombo G, Scorza-Smeraldi R, Momigliano-Richardi P. Systemic lupus erythematosus candidate genes in the Italian population: evidence for a significant association with interleukin-10. Arthritis Rheum 2000;43: 120-8.
113. Lazarus M, Hajeer AH, Turner D, Sinnott P, Worthington J, Ollier WE, et al. Genetic variation in the interleukin 10 gene promoter and systemic lupus erythematosus. J Rheumatol 1997;24: 2314-7.
114. Mok CC, Lanchbury JS, Chan DW, Lau CS. Interleukin-10 promoter polymorphisms in southern Chinese patients with systemic lupus erythematosus. Arthritis Rheum 1998;41:1090-5.
115. Gibson AW, Edberg JC, Wu J, Westendorp RG, Huizinga TW, Kimberly RP. Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus. J Immunol 2001;166: 3915-22.
116. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 1997;24:328-32.
117. Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001;27: 140-6.
118. Jimenez SA, Christner PJ. Murine animal models of systemic sclerosis. Curr Opin Rheumatol 2002;14:671-80.
119. Simms RW, Korn JH. Cytokine directed therapy in scleroderma: rationale, current status, and the future. Curr Opin Rheumatol 2002;14:717-22.
120. Yamamoto T, Eckes B, Krieg T. Effect of interleukin-10 on the gene expression of type I collagen, fibronectin, and decorin in human skin fibroblasts: differential regulation by transforming growth factor-beta and monocyte chemoattractant protein-1. Biochem Biophys Res Commun 2001;281:200-5.
121. Bhol KC, Rojas AI, Khan IU, Ahmed AR. Presence of interleukin 10 in the serum and blister fluid of patients with pemphigus vulgaris and pemphigoid. Cytokine 2000;12:1076-83.
122. Hertl M, Riechers R. Analysis of the T cells that are potentially involved in autoantibody production in pemphigus vulgaris. J Dermatol 1999;26:748-52.
123. Toto P, Feliciani C, Amerio P, Suzuki H, Wang B, Shivji GM, et al. Immune modulation in pemphigus vulgaris: role of CD28 and IL-10. J Immunol 2000;164:522-9.
124. Giacalone B, D'Auria L, Bonifati C, Ferraro C, Riccardi E, Mussi A, et al. Decreased interleukin-7 and transforming growth factor-beta1 levels in blister fluids as compared to the respective serum levels in patients with bullous pemphigoid. Opposite behavior of TNF-alpha, interleukin-4 and interleukin-10. Exp Dermatol 1998;7:157-61.
125. Schmidt E, Bastian B, Dummer R, Tony HP, Brocker EB, Zillikens D. Detection of elevated levels of IL-4, IL-6, and IL-10 in blister fluid of bullous pemphigoid. Arch Dermatol Res 1996;288: 353-7.
126. D'Auria L, Mussi A, Bonifati C, Mastroianni A, Giacalone B, Ameglio F. Increased serum IL-6, TNF-alpha and IL-10 levels in patients with bullous pemphigoid: relationships with disease activity. J Eur Acad Dermatol Venereol 1999;12:11-5.
127. Sun CC, Wu J, Wong TT, Wang LF, Chuan MT. High levels of interleukin-8, soluble CD4 and soluble CD8 in bullous pemphigoid blister fluid. The relationship between local cytokine production and lesional T-cell activities. Br J Dermatol 2000;143: 1235-40.
128. Teraki Y, Hotta T, Shiohara T. Skin-homing interleukin-4 and -13-producing cells contribute to bullous pemphigoid: remission of disease is associated with increased frequency of interleukin-10-producing cells. J Invest Dermatol 2001;117: 1097-102.
129. Freyschmidt-Paul P, Seiter S, Zoller M, Konig A, Ziegler A, Sundberg JP, et al. Treatment with an anti-CD44v10-specific antibody inhibits the onset of alopecia areata in C3H/HeJ mice. J Invest Dermatol 2000;115:653-7.
130. Hoffmann R, Happle R. Topical immunotherapy in alopecia areata. What, how, and why? Dermatol Clin 1996;14:739-44.
131. Hoffmann R, Wenzel E, Huth A, van der Steen P, Schaufele M, Henninger HP, et al. Cytokine mRNA levels in alopecia areata before and after treatment with the contact allergen diphenylcyclopropenone. J Invest Dermatol 1994;103:530-3.
132. Freyschmidt-Paul P, McElwee KJ, Happle R, Kissling S, Wenzel E, Sundberg JP, et al. Interleukin-10-deficient mice are less susceptible to the induction of alopecia areata. J Invest Dermatol 2002;119:980-2.
133. Craven NM, Jackson CW, Kirby B, Perrey C, Pravica V, Hutchinson IV, et al. Cytokine gene polymorphisms in psoriasis. Br J Dermatol 2001;144:849-53.
134. Lebeaut A, Garaud JJ. Clinical development of interleukin-10. Eur Cytokine Netw 1997;8:303-4.
135. Asadullah K, Eskdale J, Wiese A, Gallagher G, Friedrich M, Sterry W. Interleukin-10 promoter polymorphism in psoriasis. J Invest Dermatol 2001;116:975-8.
136. Nishigori C, Yarosh DB, Ullrich SE, Vink AA, Bucana CD, Roza L, et al. Evidence that DNA damage triggers interleukin 10 cytokine production in UV-irradiated murine keratinocytes. Proc Natl Acad Sci USA 1996;93:10354-9.
137. Kang K, Gilliam AC, Chen G, Tootell E, Cooper KD. In human skin, UVB initiates early induction of IL-10 over IL-12 preferentially in the expanding dermal monocytic/macrophagic population. J Invest Dermatol 1998;111:31-8.
138. Brink N, Szamel M, Young AR, Wittern KP, Bergemann J. Comparative quantification of IL-1 beta, IL-10, IL-10r, TNFalpha and IL-7 mRNA levels in UV-irradiated human skin in vivo. Inflamm Res 2000;49:290-6.
139. Curiel-Lewandrowski C, Venna SS, Eller MS, Cruikshank W, Dougherty I, Cruz PD, et al. Inhibition of the elicitation phase of contact hypersensitivity by thymidine dinucleotides is in part mediated by increased expression of interleukin-10 in human keratinocytes. Exp Dermatol 2003;12:145-52.
140. Kang K, Hammerberg C, Meunier L, Cooper KD. CD11b+ macrophages that infiltrate human epidermis after in vivo ultraviolet exposure potently produce IL-10 and represent the major secretory source of epidermal IL-10 protein. J Immunol 1994; 153:5256-64.
141. Friedrich M, Docke WD, Klein A, Philipp S, Volk HD, Sterry W, et al. Immunomodulation by interleukin-10 therapy decreases the incidence of relapse and prolongs the relapse-free interval in psoriasis. J Invest Dermatol 2002;118:672-7.
142. Asadullah K, Docke WD, Ebeling M, Friedrich M, Belbe G, Audring H, et al. Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial. Arch Dermatol 1999;135:187-92.
143. Reich K, Garbe C, Blaschke V, Maurer C, Middel P, Westphal G, et al. Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation. J Invest Dermatol 2001; 116:319-29.
144. McInnes IB, Illei GG, Danning CL, Yarboro CH, Crane M, Kuroiwa T, et al. IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis. J Immunol 2001;167:4075-82.
145. Kimball AB, Kawamura T, Tejura K, Boss C, Hancox AR, Vogel JC, et al. Clinical and immunologic assessment of patients with psoriasis in a randomized, double-blind, placebo-controlled trial using recombinant human interleukin 10. Arch Dermatol 2002;138:1341-6.
146. Pretolani M. Interleukin-10: an anti-inflammatory cytokine with therapeutic potential. Clin Exp Allergy 1999;29:1164-71.
147. Blauvelt A, Hwang ST, Udey MC. Allergic and immunologic diseases of the skin. J Allergy Clin Immunol 2003;111(Suppl): S560-70.
148. 8erg DJ, Leach MW, Kuhn R, Rajewsky K, Muller W, Davidson NJ, et al. Interleukin 10 but not interleukin 4 is a natural suppressant of cutaneous inflammatory responses. J Exp Med 1995; 182:99-108.
149. Akdis M, Simon HU, Weigl L, Kreyden O, Blaser K, Akdis CA. Skin homing (cutaneous lymphocyte-associated antigen-positive) CD8+ T cells respond to superantigen and contribute to eosinophilia and IgE production in atopic dermatitis. J Immunol 1999;163:466-75.
150. Aleksza M, Lukacs A, Antal-Szalmas P, Hunyadi J, Szegedi A. Increased frequency of intracellular interleukin (IL)-13 and IL-10, but not IL-4, expressing CD4+ and CD8+ peripheral T cells of patients with atopic dermatitis. Br J Dermatol 2002;147:1135-41.
151. Lewis DB. Allergy immunotherapy and inhibition of Th2 immune responses: a sufficient strategy? Curr Opin Immunol 2002;14:644-51.
152. Eichenfield LF, Beck L. Elidel (pimecrolimus) cream 1%: a non-steroidal topical agent for the treatment of atopic dermatitis. J Allergy Clin Immunol 2003;111:1153-68.
153. Watanabe H, Unger M, Tuvel B, Wang B, Sauder DN. Contact hypersensitivity: the mechanism of immune responses and T cell balance. J Interferon Cytokine Res 2002;22:407-12.
154. Wang B, Fujisawa H, Zhuang L, Freed I, Howell BG, Shahid S, et al. CD4+ Thl and CD8+ type 1 cytotoxic T cells both play a crucial role in the full development of contact hypersensitivity. J Immunol 2000;165:6783-90.
155. Wang B, Zhuang L, Fujisawa H, Shinder GA, Feliciani C, Shivji GM, et al. Enhanced epidermal Langerhans cell migration in IL-10 knockout mice. J Immunol 1999;162:277-83.
156. Kondo S, Pastore S, Shivji GM, McKenzie RC, Sauder DN. Characterization of epidermal cytokine profiles in sensitization and elicitation phases of allergic contact dermatitis as well as irritant contact dermatitis in mouse skin. Lymphokine Cytokine Res 1994;13:367-75.
157. Schwarz A, Grabbe S, Riemann H, Aragane Y, Simon M, Manon S, et al. In vivo effects of interleukin-10 on contact hypersensitivity and delayed-type hypersensitivity reactions. J Invest Dermatol 1994;103:211-6.
158. Ferguson TA, Dube P, Griffith TS. Regulation of contact hypersensitivity by interleukin 10. J Exp Med 1994;179:1597-604.
159. Kondo S, McKenzie RC, Sauder DN. Interleukin-10 inhibits the elicitation phase of allergic contact hypersensitivity. J Invest Dermatol 1994;103:811-4.
160. Enk AH, Angeloni VL, Udey MC, Katz SI. Inhibition of Langerhans cell antigen-presenting function by IL-10. A role for IL-10 in induction of tolerance. J Immunol 1993;151:2390-8.
161. Liew FY. Induction and regulation of CD4+ T cell subsets. Ciba Found Symp 1994;187:170-5; discussion, 176-8.
162. Salazar-Onfray F. Interleukin-10: a cytokine used by tumors to escape immunosurveillance. Med Oncol 1999;16:86-94.
163. Costello RT, Gastaut JA, Olive D. Mechanisms of tumor escape from immunologic response [in French]. Rev Med Interne 1999;20:579-88.
164. Salazar-Onfray F, Charo J, Petersson M, Freland S, Noffz G, Qin Z, et al. Down-regulation of the expression and function of the transporter associated with antigen processing in murine tumor cell lines expressing IL-10. J Immunol
165. Lazar-Molnar E, Hegyesi H, Toth S, Falus A. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 2000;12:547-54.
166. Nemunaitis J, Fong T, Shabe P, Martineau D, Ando D. Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma. Cancer Invest 2001;19:239-47.
167. Howell WM, Turner SJ, Bateman AC, Theaker JM. IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun 2001;2:25-31.
168. Dummer W, Bastian BC, Ernst N, Schanzle C, Schwaaf A, Brocker EB. Interleukin-10 production in malignant melanoma: preferential detection of IL-10-secreting tumor cells in metastatic lesions. Int J Cancer 1996;66:607-10.
169. Kruger-Krasagakis S, Krasagakis K, Garbe C, Schmitt E, Huls C, Blankenstein T, et al. Expression of interleukin 10 in human melanoma. Br J Cancer 1994;70:1182-5.
170. Steinbrink K, Jonuleit H, Muller G, Schuler G, Knop J, Enk AH. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. Blood 1999;93:1634-42.
171. Huang S, Ullrich SE, Bar-Eli M. Regulation of tumor growth and metastasis by interleukin-10: the melanoma experience. J Interferon Cytokine Res 1999;19:697-703.
172. Gjersvik PJ. [Etiology of nonmelanoma skin cancer]. Tidsskr Nor Laegeforen 2001;121:2052-6. Norwegian.
173. Gervin CM, McCulla A, Williams M, Ouhtit A. Dysfunction of p53 in photocarcinogenesis. Front Biosci 2003;8(Suppl):S715-7.
174. Williams JA, Guicherit OM, Zaharian BI, Xu Y, Chal L, Wichterle H, et al. Identification of a small molecule inhibitor of the hedgehog signaling pathway: effects on basal cell carcinoma-like lesions. Proc Natl Acad Sci USA 2003;100:4616-21.
175. Enk CD, Mahanty S, Blauvelt A, Katz SI. UVB induces IL-12 transcription in human keratinocytes in vivo and in vitro. Photochem Photobiol 1996;63:854-9.
176. Kim J, Modlin RL, Moy RL, Dubinett SM, McHugh T, Nickoloff BJ, et al. IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. J Immunol 1995;155:2240-7.
177. Karcher J, Reisser C, Daniel V, Herold-Mende C. [Cytokine expfession of transforming growth factor-beta2 and interleukin-10 in squamous cell carcinomas of the head and neck. Comparison of tissue expression and serum levels]. HNO 1999; 47:879-84. German.
178. Kooy AJ, Prens EP, Van Heukelum A, Vuzevski VD, Van Joost T, Tank B. Interferon-gamma-induced ICAM-1 and CD40 expression, complete lack of HLA-DR and CD80 (B7.1), and inconsistent HLA-ABC expression in basal cell carcinoma: a possible role for interleukin-10? J Pathol 1999;187:351-7.
179. Agarwal A, Rani M, Saha GK, Valarmathi TM, Bahadur S, Mohanti BK, et al. Disregulated expression of the Th2 cytokine gene in patients with intraoral squamous cell carcinoma. Immunol Invest 2003;32:17-30.
180. Fujieda S, Sunaga H, Tsuzuki H, Fan GK, Saito H. IL-10 expression is associated with the expression of platelet-derived endothelial cell growth factor and prognosis in oral and oropharyngeal carcinoma. Cancer Lett 1999;136:1-9.
181. Young MR, Wright MA, Lozano Y, Matthews JP, Benefield J, Prechel MM. Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer. Int J Cancer 1996;67:333-8.
182. Willemze R, Kerl H, Sterry W, Berti E, Cerroni L, Chimenti S, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997;90:354-71.
183. Asadullah K, Docke WD, Haeussler A, Sterry W, Volk HD. Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA. J Invest Dermatol 1996;107:833-7.
184. Asadullah K, Gellrich S, Haeussler-Quade A, Friedrich M, Docke WD, Jahn S, et al: Cytokine expression in primary cutaneous germinal center cell lymphomas. Exp Dermatol 2000;9:71-6.
185. Nickoloff BJ, Fivenson DP, Kunkel SL, Strieter RM, Turka LA. Keratinocyte interleukin-10 expression is upregulated in tape-stripped skin, poison ivy dermatitis, and Sezary syndrome, but not in psoriatic plaques. Clin Immunol Immunopathol 1994;73:63-8.
186. Edelson RL. Cutaneous T cell lymphoma: mycosis fungoides, Sezary syndrome, and other variants. J Am Acad Dermatol 1980;2:89-106.
187. Schreiber S, Fedorak RN, Nielsen OH, Wild G, Williams CN, Nikolaus S, et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology 2000;119: 1461-72.
188. Tao M, Li B, Nayini J, Sivaraman S, Song S, Larson A, et al. In vivo effects of IL-4, IL-10, and amifostine on cytokine production in patients with acute myelogenous leukemia. Leuk Lymphoma 2001;41:161-8.
189. Pajkrt D, Camoglio L, Tiel-van Buul MC, de Bruin K, Cutler DL, Affrime MB, et al. Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia: effect of timing of recombinant human IL-10 administration. J Immunol 1997;158:3971-7.
190. Rott O, Fleischer B, Cash E. Interleukin-10 prevents experimental allergic encephalomyelitis in rats. Eur J Immunol 1994;24: 1434-40.
191. Van Laethem JL, Marchant A, Delvaux A, Goldman M, Robberecht P, Velu T, et al. Interleukin 10 prevents necrosis in murine experimental acute pancreatitis. Gastroenterology 1995;108: 1917-22.
192. Pennline KJ, Roque-Gaffney E, Monahan M. Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin Immunol Immunopathol 1994;71:169-75.
193. Persson S, Mikulowska A, Narula S, O'Garra A, Holmdahl R. Interleukin-10 suppresses the development of collagen type II-induced arthritis and ameliorates sustained arthritis in rats. Scand J Immunol 1996;44:607-14.